 WALTHAM, Mass., April 01, 2021 GLOBE NEWSWIRE -- EyeGate Pharmaceuticals, Inc. NASDAQ: EYEG, EyeGate or the Company, a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Companys Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company. 